Viatris’ Mylan And Apotex Lose Again Over US Bendeka Patents
ANDA Sponsors Continue To Be Barred From Launch Until 2031
Viatris’ Mylan and Apotex once again fell to Teva and Eagle Pharmaceuticals in their battle to introduce generic versions of the rapid-infusion bendamustine formulation, Bendeka, with the US Federal Circuit upholding a lower court judgement.
